FI109207B - Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja - Google Patents

Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja Download PDF

Info

Publication number
FI109207B
FI109207B FI935970A FI935970A FI109207B FI 109207 B FI109207 B FI 109207B FI 935970 A FI935970 A FI 935970A FI 935970 A FI935970 A FI 935970A FI 109207 B FI109207 B FI 109207B
Authority
FI
Finland
Prior art keywords
antibody
tyr
cell line
antigen
leu
Prior art date
Application number
FI935970A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935970A0 (fi
FI935970L (fi
Inventor
Jan Holmgren
Peter Lind
Leif Lindholm
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI935970A0 publication Critical patent/FI935970A0/fi
Publication of FI935970L publication Critical patent/FI935970L/fi
Application granted granted Critical
Publication of FI109207B publication Critical patent/FI109207B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI935970A 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja FI109207B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
SE9102074 1991-07-03
SE9200502 1992-07-03
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Publications (3)

Publication Number Publication Date
FI935970A0 FI935970A0 (fi) 1993-12-31
FI935970L FI935970L (fi) 1993-12-31
FI109207B true FI109207B (fi) 2002-06-14

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935970A FI109207B (fi) 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja

Country Status (19)

Country Link
US (1) US5552293A (enExample)
EP (1) EP0521842B1 (enExample)
JP (1) JP3194020B2 (enExample)
KR (1) KR100246681B1 (enExample)
AT (1) ATE171193T1 (enExample)
AU (2) AU658198B2 (enExample)
CA (1) CA2073124C (enExample)
DE (1) DE69226990T2 (enExample)
DK (1) DK0521842T3 (enExample)
EE (1) EE03031B1 (enExample)
ES (1) ES2124250T3 (enExample)
FI (1) FI109207B (enExample)
HU (2) HU218084B (enExample)
IE (1) IE80841B1 (enExample)
IL (1) IL102390A (enExample)
NO (1) NO315472B1 (enExample)
NZ (1) NZ243435A (enExample)
SE (1) SE9102074D0 (enExample)
WO (2) WO1993001302A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
TR199902553T2 (xx) * 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004537976A (ja) * 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
NZ537610A (en) * 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101145506B1 (ko) 2003-05-20 2012-05-15 이뮤노젠 아이엔씨 새로운 메이탠시노이드를 포함하는 개선된 세포독성체
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
JP5165387B2 (ja) 2005-02-11 2013-03-21 イムノゲン インコーポレーティッド 安定な薬物複合体を調製するための方法
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
GB2429013C (en) * 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
EP3539572A1 (en) 2005-08-24 2019-09-18 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US11137401B2 (en) 2008-08-05 2021-10-05 Toray Industries, Inc. Method for detecting cancer using CAPRIN-1 as a marker
EP2437790B1 (en) 2009-06-03 2019-02-20 Immunogen, Inc. Conjugation methods
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
TR201902180T4 (tr) 2011-03-29 2019-03-21 Immunogen Inc Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
EA201891601A1 (ru) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
JP2019510741A (ja) 2016-02-05 2019-04-18 イミュノジェン・インコーポレーテッド 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
EA202193121A1 (ru) 2019-05-15 2022-02-21 Неоткс Терапьютикс Лтд. Лечение рака
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
EP4732850A1 (en) 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
CA2087163A1 (en) * 1990-07-20 1992-01-21 Hubert Agback Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
ES2094231T3 (es) * 1990-07-20 1997-01-16 Pharmacia & Upjohn Ab Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Also Published As

Publication number Publication date
IL102390A (en) 1996-01-19
EE03031B1 (et) 1997-08-15
WO1993001303A1 (en) 1993-01-21
DK0521842T3 (da) 1999-06-14
KR100246681B1 (ko) 2000-04-01
HU211512A9 (en) 1995-11-28
NZ243435A (en) 1994-10-26
HU218084B (hu) 2000-05-28
FI935970A0 (fi) 1993-12-31
HUT71193A (en) 1995-11-28
FI935970L (fi) 1993-12-31
DE69226990T2 (de) 1999-03-25
ATE171193T1 (de) 1998-10-15
US5552293A (en) 1996-09-03
EP0521842A3 (enExample) 1994-01-26
DE69226990D1 (de) 1998-10-22
CA2073124A1 (en) 1993-01-04
AU658198B2 (en) 1995-04-06
EP0521842A2 (en) 1993-01-07
IE922188A1 (en) 1993-01-13
ES2124250T3 (es) 1999-02-01
AU2292092A (en) 1993-02-11
CA2073124C (en) 2007-06-19
IE80841B1 (en) 1999-03-24
JP3194020B2 (ja) 2001-07-30
SE9102074D0 (sv) 1991-07-03
AU1942592A (en) 1993-01-07
NO934777D0 (no) 1993-12-22
IL102390A0 (en) 1993-01-14
WO1993001302A1 (en) 1993-01-21
EP0521842B1 (en) 1998-09-16
JPH05276987A (ja) 1993-10-26
HU9400011D0 (en) 1994-05-30
NO934777L (no) 1994-02-11
NO315472B1 (no) 2003-09-08

Similar Documents

Publication Publication Date Title
EP0521842B1 (en) Tumor antigen specific antibody
JP3492373B2 (ja) モノクローナル抗体
CN111777681B (zh) 一种结合紧密连接蛋白-18.2的抗体及其用途
JP4124486B2 (ja) ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
CN114514246A (zh) 对nectin-4具有特异性的抗体及其用途
JP2000511421A5 (enExample)
JP2001501801A (ja) モノクローナル抗体ｂｒ１１０およびその使用
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
EP4257612A1 (en) Development of new tumor engager therapeutic drug and use thereof
IE60286B1 (en) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas
JP2007535907A (ja) 抗ヒドロキシラーゼ抗体およびその使用
EP3543259A2 (en) Antibody binding to carbonic anhydrase and use thereof
EP3601364A1 (en) Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
US6787638B1 (en) Tumor specific human monoclonal antibodies and methods of use
RU2268068C2 (ru) Новое антитело со специфичностью к злокачественной опухоли толстой кишки
WO2021229104A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP4149543A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment
CN101389756A (zh) 单克隆抗体、编码该抗体的基因、杂交瘤、药物组合物和诊断试剂

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB

MA Patent expired